Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Controlled Trial ◽

Metastatic Breast ◽

Randomized Controlled ◽

Abstract P1-14-01: Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior non-steroidal aromatase inhibitor treatment in postmenopausal women with hormone receptor-positive metastatic breast cancer (Hi-FAIR ex study)

10.1158/0008-5472.sabcs13-p1-14-01 ◽

2013 ◽

Author(s):

Y Yamamoto ◽

T Ishikawa ◽

Y Hozumi ◽

M Ikeda ◽

N Kondo ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Controlled Trial ◽

Metastatic Breast ◽

Randomized Controlled ◽

Aromatase Inhibitor Treatment ◽

Inhibitor Treatment

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3015-6 ◽

2014 ◽

Vol 146 (1) ◽

pp. 153-162 ◽

Cited By ~ 24

Author(s):

Mark J. Clemons ◽

Brandy Cochrane ◽

Gregory R. Pond ◽

Nadia Califaretti ◽

Stephen K. L. Chia ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Phase Ii ◽

Hormone Receptor ◽

Controlled Trial ◽

Metastatic Breast ◽

Abstract P3-11-02: A randomized phase II trial of toremifene (120 mg) versus fulvestrant (500 mg) after prior non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer (Hi-FAIR fx study)

10.1158/1538-7445.sabcs17-p3-11-02 ◽

2018 ◽

Author(s):

R Nishimura ◽

Y Yamamoto ◽

K Narui ◽

Y Kijima ◽

Y Hozumi ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Randomized Phase Ii

Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: Rationale and design of a randomized controlled trial

Contemporary Clinical Trials ◽

10.1016/j.cct.2011.04.012 ◽

2011 ◽

Vol 32 (5) ◽

pp. 704-709 ◽

Cited By ~ 5

Author(s):

Sharon Kilbreath ◽

Kathryn M. Refshauge ◽

Jane Beith ◽

Leigh Ward ◽

Kate Sawkins ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Early Breast Cancer ◽

Controlled Trial ◽

Inhibitor Therapy ◽

Aromatase Inhibitor Therapy ◽

Randomized Controlled ◽

Prevention Of Osteoporosis

PD01-01: Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor.

10.1158/0008-5472.sabcs11-pd01-01 ◽

2011 ◽

Cited By ~ 6

Author(s):

GL Wright ◽

J Blum ◽

LK Krekow ◽

KJ McIntyre ◽

ST Wilks ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Previously Treated

Abstract OT3-2-10: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy

10.1158/0008-5472.sabcs13-ot3-2-10 ◽

2013 ◽

Cited By ~ 2

Author(s):

N Turner ◽

F André ◽

S Loibl ◽

J Ro ◽

H Iwata ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Controlled Trial ◽

Metastatic Breast ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Abstract CT330: Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

10.1158/1538-7445.am2015-ct330 ◽

2015 ◽

Cited By ~ 3

Author(s):

Payal D. Shah ◽

Mary E. Moynahan ◽

Shanu Modi ◽

Nicola Hamilton ◽

Betty Ann Caravella ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Phase I Study ◽

Metastatic Breast ◽

First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

Breast Cancer ◽

10.1007/s12282-019-01034-6 ◽

2019 ◽

Vol 27 (3) ◽

pp. 399-404 ◽

Cited By ~ 1

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

Qiuji Wu ◽

Feng Wen ◽

Nan Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis

Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer

Investigational New Drugs ◽

10.1007/s10637-016-0403-2 ◽

2016 ◽

Vol 35 (1) ◽

pp. 87-94 ◽

Cited By ~ 3

Author(s):

Murtuza Rampurwala ◽

Kari B. Wisinski ◽

Mark E. Burkard ◽

Sima Ehsani ◽

Ruth M. O’Regan ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 1B

A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer

Psycho-Oncology ◽

10.1002/(sici)1099-1611(199811/12)7:6<508::aid-pon376>3.0.co;2-7 ◽

1998 ◽

Vol 7 (6) ◽

pp. 508-517 ◽

Cited By ~ 152

Author(s):

A.J. Cunningham ◽

C.V.I. Edmonds ◽

G.P. Jenkins ◽

H. Pollack ◽

G.A. Lockwood ◽

...

Keyword(s):

Breast Cancer ◽

Controlled Trial ◽

Metastatic Breast ◽

Psychological Therapy ◽

Randomized Controlled